Form D · Biotechnology
Abfero Pharmaceuticals, Inc.
Lexington, MA · CIK 0001769029
Offering snapshot reported Mar 23, 2021 · SEC filing
- Reported sold
- $500K Offering amount: $1M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Mar 22, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 23, 2021 | Initial | $500,000 | No comparison | 2 | SEC filing |
| Jun 24, 2020 | Initial | $680,000 | No comparison | 4 | SEC filing |
| Apr 11, 2019 | Amendment | $600,000 | $300,000vs Feb 27, 2019 | 6 | SEC filing |
| Feb 27, 2019 | Initial | $300,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-393097
Source: Form D, filed Mar 23, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven Burke | Director, Executive |
| Thomas X Neenan | Director, Executive |
| Michael Penington | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
405 Waltham Street Suite 353
Lexington, MA, 02421
Lexington, MA, 02421